NEW YORK (GenomeWeb) – Belgian diagnostics firm VolitionRx said today that it has acquired a patent family around nucleosome analysis in cancer from Chroma Therapeutics.
The patent family, WO 2005/019826, was originally filed by UK-based Chroma and exclusively licensed to VolitionRx.
The IP covers the detection of histone modifications in cell-free nucleosomes from circulating cancer cells. VolitionRx, based in Namur, owns other patents covering the analysis of nucleosomes and chromatin fragment structures. The company is developing blood-based diagnostic tests for cancer and other conditions.
"Having all the core Nucleosomics IP completely royalty free is a very positive outcome for the retention of the value we aim to create for our shareholders," said VolitionRx CEO Cameron Reynolds in a statement.
The company, which raised $8.5 million in an initial public offering earlier this month, plans to market its diagnostic products in Europe first, followed by the US and other regions.